Kura Oncology, Inc. $KURA Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC decreased its stake in Kura Oncology, Inc. (NASDAQ:KURA) by 60.4% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 52,003 shares of the company’s stock after selling 79,189 shares during the quarter. Hsbc Holdings PLC owned approximately 0.06% of Kura Oncology worth $536,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of KURA. Virtu Financial LLC purchased a new position in Kura Oncology during the fourth quarter valued at approximately $349,000. Invesco Ltd. boosted its position in Kura Oncology by 14.6% in the 4th quarter. Invesco Ltd. now owns 209,370 shares of the company’s stock worth $2,175,000 after purchasing an additional 26,683 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in Kura Oncology by 52.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 50,080 shares of the company’s stock worth $520,000 after purchasing an additional 17,197 shares in the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Kura Oncology during the 4th quarter worth approximately $2,505,000. Finally, Virtus Investment Advisers LLC grew its stake in shares of Kura Oncology by 291.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 66,870 shares of the company’s stock worth $695,000 after purchasing an additional 49,785 shares during the period.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 84,929 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $9.82, for a total value of $834,002.78. Following the completion of the transaction, the insider directly owned 182,345 shares of the company’s stock, valued at approximately $1,790,627.90. This represents a 31.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Jefferies Financial Group set a $24.00 price target on shares of Kura Oncology in a report on Thursday, May 28th. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 price objective on shares of Kura Oncology in a research report on Monday, June 15th. CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research report on Monday, June 15th. Finally, Lake Street Capital began coverage on Kura Oncology in a research note on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target for the company. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.46.

Kura Oncology Price Performance

NASDAQ:KURA opened at $10.89 on Friday. The stock has a 50 day moving average of $10.14 and a two-hundred day moving average of $9.26. Kura Oncology, Inc. has a 12 month low of $5.45 and a 12 month high of $12.49. The firm has a market cap of $966.71 million, a P/E ratio of -3.25 and a beta of 0.35. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.05. The business had revenue of $18.27 million for the quarter, compared to the consensus estimate of $25.97 million. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%. On average, analysts expect that Kura Oncology, Inc. will post -3.45 earnings per share for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.